Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10153776 | 0.84 | ALDH1A1 (0.42) | FDPSALDH1A1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL11247982 | 0.82 | FDPS (0.44) | FDPSALDH1A1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL4759129 | 0.82 | — | — | |
| SCHEMBL3638066 | 0.81 | FDPS (0.43) | FDPSALDH1A1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL26865302 | 0.80 | HTT (0.45) | FDPSALDH1A1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL6959399 | 0.79 | HTT (0.46) | FDPSALDH1A1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL27521697 | 0.79 | ALDH1A1 (0.42) | FDPSALDH1A1PKMRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL5529731 | 0.78 | HTT (0.45) | FDPSALDH1A1PKMRAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27680689 | 0.78 | HTT (0.45) | FDPSALDH1A1PKMRAB9ASMN1; SMN2 | |
| SCHEMBL3428398 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | claimed |
| EP-3050873-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | claimed |
| EP-2651893-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-03-30 | — | — | EP | claimed |
| EP-2651893-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9663460-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170050925-A9 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3050873-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2651893-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-1802615-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044955-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| US-6352994-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2002-03-05 | — | — | US | disclosed |
| US-20010018438-A1 | Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands | MERCK SHARP & DOHME LIMITED | 2001-08-30 | — | — | US | disclosed |
| US-6200982-B1 | USEFUL IN THERAPY OF DELETERIOUS MENTAL STATES | MERCK & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0994873-A1 | SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABA A?ALPHA 2/3 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998055480-A1 | SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABAAALPHA 2/3 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050925-A9 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | FDPS 1421/4885ALDH1A1 2553/4885PKM 3100/4885 |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | FDPS 1421/4885ALDH1A1 2553/4885PKM 3100/4885 |
| US-20010018438-A1 | Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands | GABRB2, GABRB3, GABRB1 | FDPS 2778/4885ALDH1A1 484/4885PKM 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.